Everolimus bolero 2 overall survival

Novartis reports data at EBCC-9 for secondary survival endpoint of. Progression-free or overall survivalrevisited in BOLERO-2 Gupta. 1LBA Everolimus plus exemestane for hormone receptor-positive.

Everolimus for Advanced Breast Cancer: An Update - Cancer Network. Article > Afinitor/Aromasin combo disappoints in breast cancer trial.

19 Mar 2014 Median overall survival in everolimus arm was 31 months. the longest III BOLERO-2 (Breast cancer trials of OraL EveROlimus-2) study of. 18 Sep 2012 The 18-month results of the phase III BOLERO-2 trial were presented at Overall survival data continue to be promising and even more mature. 25 Mar 2014 No statistical significance for overall survival. from the BOLERO-2 trial looking at the mTOR inhibitor Afinitor (everolimus) plus the aromatase.

Subgroup Analyses Show Depth of Everolimus Benefit in BOLERO-2

4 Jun 2014 Progression-free or overall survivalrevisited in BOLERO-2 More recently, everolimus has begun to be used in patients with metastatic. 1LBA Everolimus plus exemestane for hormone receptor-positive (HR+), human advanced breast cancer (BC): overall survival results from BOLERO-2.

The BOLERO-2 trial: the addition of everolimus to exemestane in the

Progression-free or overall survivalrevisited in BOLERO-2 Gupta. 1LBA Everolimus plus exemestane for hormone receptor-positive. 1LBA Everolimus plus exemestane for hormone receptor-positive (HR+), human advanced breast cancer (BC): overall survival results from BOLERO-2.

Novartis reports data at EBCC-9 for secondary survival - Oncotrends. Novartis reports data at EBCC-9 for secondary survival endpoint of.

Everolimus for Advanced Breast Cancer: An Update - Cancer Network.

19 Mar 2014 Median overall survival in everolimus arm was 31 months. the longest III BOLERO-2 (Breast cancer trials of OraL EveROlimus-2) study of. 4 Jun 2014 Progression-free or overall survivalrevisited in BOLERO-2 More recently, everolimus has begun to be used in patients with metastatic. 18 Sep 2012 The 18-month results of the phase III BOLERO-2 trial were presented at Overall survival data continue to be promising and even more mature.